<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(11)</volume><submitter>Santamaria S</submitter><pubmed_abstract>Commentary on 'Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19' by Sun et al.</pubmed_abstract><journal>International journal of biological sciences</journal><pagination>2770-2771</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8326129</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Targeting the PI3K/AKT pathway: a potential new weapon in the global fight against SARS-CoV-2?</pubmed_title><pmcid>PMC8326129</pmcid><pubmed_authors>Santamaria S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting the PI3K/AKT pathway: a potential new weapon in the global fight against SARS-CoV-2?</name><description>Commentary on 'Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19' by Sun et al.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2022-02-11T12:43:54.216Z</modification><creation>2022-02-11T12:43:54.216Z</creation></dates><accession>S-EPMC8326129</accession><cross_references><pubmed>34345206</pubmed><doi>10.7150/ijbs.63969</doi></cross_references></HashMap>